Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma
Sponsor: University Hospital Tuebingen
Terminated
Lack of patients
Other terminated trials from University Hospital Tuebingen
Listed as NCT03728465, this PHASE2 trial focuses on Brain Metastases and Metastatic Melanoma and remains terminated or withdrawn. Sponsored by University Hospital Tuebingen, it has been updated 5 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Buxtehude, Germany , Dresden, Germany , Erfurt, Germany , Essen, Germany , Heidelberg, Germany , Ludwigshafen, Germany , Mannheim, Germany , München, Germany , Quedlinburg, Germany , Regensburg, Germany and 1 more location